Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A new way to regulate the NMJ

A key regulator of the neuromuscular junction, the transcriptional co-activator PGC-1α, is a potential target for Duchenne muscular dystrophy therapy.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Model for the transcriptional activation by PGC-1α.

Kim Caesar


  1. Koenig, M. et al. Cell 50, 509–517 (1987).

    Article  CAS  Google Scholar 

  2. Nowak, K.J. & Davies, K.E. EMBO Rep. 5, 872–876 (2004).

    Article  CAS  Google Scholar 

  3. Bogdanovich, S. et al. Nature 420, 418–421 (2002).

    Article  CAS  Google Scholar 

  4. Khurana, T.S. & Davies, K.E. Nat. Rev. Drug Discov. 2, 379–390 (2003).

    Article  CAS  Google Scholar 

  5. Handschin, C. et al. Genes Dev. 21, 770–783 (2007).

    Article  CAS  Google Scholar 

  6. Sandri, M. et al. Proc. Natl. Acad. Sci. USA 103, 16260–16265 (2006).

    Article  CAS  Google Scholar 

  7. Angus, L.M. et al. Am. J. Physiol. Cell Physiol. 289, C908–C917 (2005).

    Article  CAS  Google Scholar 

  8. Schaeffer, L. et al. EMBO J. 17, 3078–3090 (1998).

    Article  CAS  Google Scholar 

  9. Khurana, T.S. et al. Mol. Biol. Cell 10, 2075–2086 (1999).

    Article  CAS  Google Scholar 

  10. Gramolini, A.O. et al. Proc. Natl. Acad. Sci. USA 96, 3223–3227 (1999).

    Article  CAS  Google Scholar 

  11. Tinsley, J.M. et al. Nature 384, 349–353 (1996

    Article  CAS  Google Scholar 

  12. Fredenrich, A. & Grimaldi, P.A. Diabetes and Metab. 31, 23–27 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Ethics declarations

Competing interests

K.E.D. is a major shareholder of VASTox plc., a company concerned with the development of treatments for muscular dystrophy.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Davies, K., Khurana, T. A new way to regulate the NMJ. Nat Med 13, 538–539 (2007).

Download citation

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing